Skip to main content

Table 4 Study assessments

From: REgistry-based randomized controlled trial of treatment and Duration and mortality in long-term OXygen therapy (REDOX) study protocol

Item

Baseline

3 months

12 months (study end)

Swedevox Register

X

  

 Demographics

X

  

 Height and weight

X

  

 Spirometry

X

  

 Blood gases on air and oxygen

X

  

 Primary and secondary causes of starting LTOT

X

  

 Oxygen dose, equipment and duration

X

  

 Use of long-term mechanical ventilator

X

 

X

 Date and reason of LTOT withdrawal

 

X

X

Cause of Death Register

   

 Date, place and causes of death

 

X

X

Patient Register

   

 Diagnoses/comorbidity and procedures

X

X

X

 Hospitalizations

X

X

X

Prescribed Drug Register

   

 Dispensed drug prescription

X

X

X

Clinical visits

   

 Adverse events

 

(X)a

(X)a

Patient questionnaire

   

 Self-reported oxygen utilization

 

X

X

 Breathlessness (MDP, NRS of worst, refractory, mMRC)

 

X

X

 Fatigue (FACIT-Fatigue)

 

X

X

 Self-reported physical activity (modified Grimby questionnaire)

 

X

X

 Cognitive questionnaires (BAS, IQCODE and FAQ)

 

X

X

 HRQoL (EQ -5D-5 L and CAT)

 

X

X

 Global impression of change

 

X

X

 Treatment preference

 

X

X

  1. aAdverse events will be collected at the patient’s ordinary clinical visits. Abbreviations: LTOT long-term oxygen therapy, MDP Multidimensional Dyspnea Profile, NRS numeric rating scale, mMRC modified Medical Research Council, FACIT Functional Assessment of Chronic Illness Therapy, IQCODE Informant Questionnaire on Cognitive Decline in the Elderly, BAS Brief Anosognosia Scale FAQ Functional Activities Questionnaire, HRQoL Health Related Quality of Life, CAT the COPD Assessment Test, EQ-5D-5 L = the EuroQoL 5 dimensions - 5 levels